PMID- 33217868
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20231112
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 47
DP  - 2020 Nov 20
TI  - Association of elevated inflammatory markers and severe COVID-19: A 
      meta-analysis.
PG  - e23315
LID - 10.1097/MD.0000000000023315 [doi]
LID - e23315
AB  - Our study aimed to assess the existing evidence on whether severe coronavirus 
      disease 2019 (COVID-19) is associated with elevated inflammatory markers.The 
      PubMed, Embase, Web of Science, Scopus, Chinese National Knowledge 
      Infrastructure, WanFang, and China Science and Technology Journal databases were 
      searched to identify studies published between January 1 and April 21, 2020 that 
      assayed inflammatory markers in COVID-19 patients. Three reviewers independently 
      examined the literature, extracted relevant data, and assessed the risk of 
      publication bias before including the meta-analysis studies.Fifty-six studies 
      involving 8719 COVID-19 patients were identified. Meta-analysis showed that 
      patients with severe disease showed elevated levels of white blood cell count 
      (WMD: 1.15, 95% CI: 0.78-1.52), C-reactive protein (WMD: 38.85, 95% CI: 
      31.19-46.52), procalcitonin (WMD: 0.08, 95% CI: 0.06-0.11), erythrocyte 
      sedimentation rate (WMD: 10.15, 95% CI: 5.03-15.46), interleukin-6 (WMD: 23.87, 
      95% CI: 15.95-31.78), and interleukin-10 (WMD: 2.12, 95% CI: 1.97-2.28). 
      Similarly, COVID-19 patients who died during follow-up showed significantly 
      higher levels of white blood cell count (WMD: 4.11, 95% CI: 3.25-4.97), 
      C-reactive protein (WMD: 74.18, 95% CI: 56.63-91.73), procalcitonin (WMD: 0.26, 
      95% CI: 0.11-0.42), erythrocyte sedimentation rate (WMD: 10.94, 95% CI: 
      4.79-17.09), and interleukin-6 (WMD: 59.88, 95% CI: 19.46-100.30) than 
      survivors.Severe COVID-19 is associated with higher levels of inflammatory 
      markers than a mild disease, so tracking these markers may allow early 
      identification or even prediction of disease progression.
FAU - Ji, Pan
AU  - Ji P
AUID- ORCID: 0000-0002-7961-0332
AD  - Department of Emergency Medicine, The Second Affiliated Hospital of Guangxi 
      Medical University, Nanning, China.
FAU - Zhu, Jieyun
AU  - Zhu J
FAU - Zhong, Zhimei
AU  - Zhong Z
FAU - Li, Hongyuan
AU  - Li H
FAU - Pang, Jielong
AU  - Pang J
FAU - Li, Bocheng
AU  - Li B
FAU - Zhang, Jianfeng
AU  - Zhang J
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Biomarkers)
RN  - 0 (IL10 protein, human)
RN  - 0 (IL6 protein, human)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Interleukin-6)
RN  - 0 (Procalcitonin)
RN  - 130068-27-8 (Interleukin-10)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Betacoronavirus
MH  - Biomarkers/*blood
MH  - Blood Sedimentation
MH  - C-Reactive Protein/analysis
MH  - COVID-19
MH  - Coronavirus Infections/*blood/mortality
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Inflammation
MH  - Inflammation Mediators/*blood
MH  - Interleukin-10/blood
MH  - Interleukin-6/blood
MH  - Leukocyte Count
MH  - Male
MH  - Middle Aged
MH  - Pandemics
MH  - Pneumonia, Viral/*blood/mortality
MH  - Procalcitonin/blood
MH  - SARS-CoV-2
MH  - *Severity of Illness Index
PMC - PMC7676531
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/11/22 06:00
MHDA- 2020/12/01 06:00
PMCR- 2020/11/20
CRDT- 2020/11/21 01:00
PHST- 2020/11/21 01:00 [entrez]
PHST- 2020/11/22 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
PHST- 2020/11/20 00:00 [pmc-release]
AID - 00005792-202011200-00083 [pii]
AID - MD-D-20-05468 [pii]
AID - 10.1097/MD.0000000000023315 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 20;99(47):e23315. doi: 
      10.1097/MD.0000000000023315.